Latest news
Biovica's CEO on transforming research results into business - BiostockBiostock · Tue, 04 Aug 2026 07:00:00 GMTProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer’s Trial - quiverquant.comquiverquant.com · Tue, 28 Jul 2026 10:13:00 GMTProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 10:00:00 GMTProMIS Neurosciences Inc. - Via RitzauVia Ritzau · Tue, 28 Jul 2026 10:00:00 GMTPositive Safety and Biomarker Phase 1b Results for PMN310 Mild Cognitive Impairment and Alzheimer Disease - Psychiatric TimesPsychiatric Times · Tue, 28 Jul 2026 07:00:00 GMTPMN: Interim results show strong safety and biomarker improvements for PMN310 in Alzheimer's disease - TradingViewTradingView · Tue, 28 Jul 2026 07:00:00 GMT